Oxidative stress in the development of liver cirrhosis: A comparison of two different experimental models

被引：96

作者：

Natarajan, Sathish Kumar ^{[1
]}

Thomas, Simmy ^{[1
]}

Ramamoorthy, Prabhu ^{[1
]}

Basivireddy, Jayasree ^{[1
]}

Pulimood, Anna B. ^{[1
]}

Ramachandran, Anup ^{[1
]}

Balasubramanian, Kunissery A. ^{[1
]}

机构：

[1] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Wellcome Trust Res Lab, Vellore 632004, Tamil Nadu, India

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷 / 06期

关键词：

carbon tetrachloride; liver cirrhosis; oxidative stress; subcellular organelles; thioacetamide;

D O I：

10.1111/j.1440-1746.2006.04231.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background/Aims: Oxidative stress has been implicated in liver cirrhosis. Carbon tetrachloride and thioacetamide are the most widely used models to develop cirrhosis in rats and the present study compares oxidative stress in the liver induced by these compounds at different stages of cirrhosis development. Methods:Twice-weekly intragastric or intraperitoneal administration of carbon tetrachloride or thioacetamide, respectively, produced liver cirrhosis after 3 months. Histology, serum markers and hepatic hydroxy proline content confirmed the cirrhosis. Results: An increase in oxidative stress parameters was seen in mitochondria, peroxisomes and microsomes from the liver after carbon tetrachloride or thioacetamide treatment. Oxidative stress was more severe in carbon tetrachloride treated animals than thioacetamide. Mild oxidative stress was evident at 1 and 2 months of treatment and a significant increase was seen by 3 months of treatment with either compound. By this time, frank liver cirrhosis was also observed. Conclusions: These results suggest that evidence of oxygen free radicals is also found early in the development of fibrosis and cirrhosis in both models.

引用

页码：947 / 957

页数：11

共 51 条

[1]

AEBI H, 1984, METHOD ENZYMOL, V105, P121

[2] Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044 [J].